NEW YORK and MELBOURNE, Australia, Nov. 13, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited MESO MSB today announced it will report financial results for the first quarter ended September 30, 2017 and provide a corporate update beginning at 4:30 pm ET on Tuesday, November 14, 2017 and 8:30 am AEDT on Wednesday, November 15, 2017.
The live webcast can be accessed via: http://webcasting.boardroom.media/broadcast/59ff897e6afa4a0577a982bb
The conference call will be accompanied by a slide presentation. Please log in approximately 15 minutes prior to the scheduled start time.
To access the call, dial 1 855 881 1339 (US), 1 800 558 698 (toll-free Australia) or +61 2 9007 3187 (outside of the US and Australia).
The conference identification code is: 303705.
The archived webcast will be available in the Events and Presentations section of the Investor page on the Company's website – www.mesoblast.com
About Mesoblast
Mesoblast Limited MESO MSB is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast's allogeneic, ‘off-the-shelf' cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular diseases, immune-mediated and inflammatory disorders, orthopedic disorders, and oncologic/hematologic conditions.
For further information, please contact:
Julie Meldrum
Corporate Communications
Mesoblast Limited
T: +61 3 9639 6036
E: julie.meldrum@mesoblast.com
Schond Greenway
Investor Relations
Mesoblast Limited
T: +1 212 880-2060
E: Schond.Greenway@mesoblast.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
